Ligand Partner Novartis Gets Key E.U. Approval: Roth Capital Likes It
April 07, 2016 at 09:46 AM EDT
The European Commission [EC] has expanded the label for Revolade [Promacta], developed by Ligand Pharmaceuticals Inc. (NASDAQ: LGND) ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.